Monitoring blood glucose control in diabetes mellitus: a systematic review.

Abstract

Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. Copies of the Executive Summaries are available from the NCCHTA website (see overleaf). NHS R&D HTA ProgrammeT he overall aim of the NHS R&D Health Technology Assessment (HTA) programme is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and work in the NHS. Research is undertaken in those areas where the evidence will lead to the greatest benefits to patients, either through improved patient outcomes or the most efficient use of NHS resources.The Standing Group on Health Technology advises on national priorities for health technology assessment. Six advisory panels assist the Standing Group in identifying and prioritising projects. These priorities are then considered by the HTA Commissioning Board supported by the National Coordinating Centre for HTA (NCCHTA).This report is one of a series covering acute care, diagnostics and imaging, methodology, pharmaceuticals, population screening, and primary and community care. It was identified as a priority by the Diagnostics and Imaging Panel and funded as project number 96/10/03.The views expressed in this publication are those of the authors and not necessarily those of the Standing Group, the Commissioning Board, the Panel members or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for the recommendations for policy contained herein. In particular, policy options in the area of screening will be considered by the National Screening Committee. This Committee, chaired by the Chief Medical Officer, will take into account the views expressed here, further available evidence and other relevant considerations.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work either prioritised by the Standing Group on Health Technology, or otherwise commissioned for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study

“…The provision of gastroprotection for nonsteroidal anti-inflammatory drug (NSAID) users is effective to prevent gastrointestinal events [27,28] and is also cost effective although this is mostly dependent on the price of the protective treatment, which can differ in different health care settings [29,30]. Monitoring of blood glucose levels in diabetic patients can prevent hypoglycemia or hyperglycemia [31] and will be cost effective in certain patient groups [32,33]. Several laxatives are effective to treat constipation [34,35], but there are not sufficient data on cost-effectiveness of different laxatives and treatment strategies in the management of constipation or opiate-related constipation.…”

Prospects and limitations of non-invasive blood glucose monitoring using near-infrared spectroscopy

“…1. Poorly managed diabetes leads to serious complications such as cardiovascular diseases, damage of blood vessels, stroke, blindness, chronic kidney failure, nervous system diseases and even amputation of the foot due to ulceration in extreme cases [5][6][7][8]. Health spending on diabetes accounted for 10.8% (548 billion USD) of total health expenditure worldwide in 2013.…”

Local release of masitinib alters in vivo implantable continuous glucose sensor performance

“…Tight regulation of blood glucose has been convincingly shown to reduce diabetes morbidity and mortality (Coster et al, 2000), leading to a standard of care that demands intensive glucose monitoring. While most glucose monitoring involves painful, inconvenient finger sticks to extract blood, subcutaneous continuous glucose monitoring (CGM) sensors have been clinically available since 1999 as an alternative (Bode et al, 1999;Chase et al, 2001;Ludvigsson and Hanas, 2003;Tanenberg et al, 2004).…”